Quantcast
 
New book by Larry Connors Click here Improve your trading - See how


 

Helix BioMedix Finalizes Clinical Studies of SmartPeptides Products

Mon. November 02, 2009; Posted: 11:32 PM
Stocks RSS
Nov 03, 2009 (Close-Up Media via COMTEX) -- HXBM | Quote | Chart | News | PowerRating -- Helix BioMedix, Inc., a developer of bioactive peptides, announced the completion of a series of three clinical studies investigating the safety and efficacy of a serum, eye cream and moisturizer, each containing the Company's SmartPeptides technology, including the newly developed Heptapeptide-7.

In a release, the Company noted that these studies demonstrate improvement in skin texture and appearance as well as the decrease in fine lines and wrinkles with Striking Skin Care formulations.

"Our SmartPeptides technology found in Striking Skin Care products performed well in clinical evaluation with high consumer appeal," said Dr. Tim Falla, Chief Scientific Officer at Helix BioMedix. "We are delighted with the results of these third-party studies documenting the benefits of SmartPeptides technology for people seeking improved skin texture and hydration. We plan to present the studies at upcoming dermatology conferences, while we wait for publication of the complete study."

The Company said that it is in the process of submitting study synopsis articles for publication in leading peer reviewed journals.

All three studies were conducted by Essex Testing Clinic, Inc (Verona, NJ) over an eight week period with evaluations at baseline, eight hours and at two, four and eight weeks. Evaluations consisted of physician and patient assessments as well as measurements of skin hydration, topography and texture using Corneometer, Visia CR and ImagePro instrumentation.

As described by the Company, summary findings of the studies are as follows:

Serum: In a 32 person study (average age 54) the Striking Skin Care serum produced a statistical improvement in vertical forehead lines with 74 percent of subjects showing improvement. A statistical improvement was also seen in skin texture with 87 percent of subjects showing improvement. Reductions in forehead wrinkles could be seen as early as two weeks in certain individuals.

Eye: A 30 person study (average age 52) documented a statistical reduction in the appearance of crow's feet was seen with 97 percent of subjects showing improvement. From the earliest time point of 8 hours, subjects exhibited a statistical improvement in skin texture and moisturization with 100 percent and 83 percent showing improvement respectively.

Moisturizer: In a 30 person study (average age 51) the Striking Skin Care moisturizer produced a statistical improvement in skin hydration at all time points from 8 hours through 8 weeks with 87 percent of participants showing improvement. Statistical improvement in skin texture was also seen with 87 percent of people showing an improvement; in certain individuals this was apparent after only two weeks.

No irritation or adverse effects were reported throughout these third party studies or in repeat patch test insult studies run in parallel. In all studies statistical significance was taken as p less than or equal to 0.005.

((Comments on this story may be sent to newsdesk@closeupmedia.com))

For full details for HXBM click here.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Related News [HXBM]
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.